L3VLUP
ProSign in

ALC · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ALCVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ALC
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterALCVRTX
Q3 202012 holders, $2.5bn31 holders, $21.9bn
Q4 202011 holders, $2.1bn30 holders, $18.4bn
Q1 202113 holders, $2.2bn31 holders, $15.4bn
Q2 20218 holders, $1.7bn30 holders, $12.7bn
Q3 20217 holders, $2.2bn35 holders, $10.1bn
Q4 20217 holders, $2.4bn28 holders, $12.4bn
Q1 20228 holders, $3.0bn23 holders, $16.1bn
Q2 20227 holders, $2.4bn25 holders, $18.1bn
Q3 202210 holders, $1.0bn22 holders, $18.4bn
Q4 202213 holders, $1.4bn28 holders, $18.4bn
Q1 202313 holders, $1.4bn26 holders, $21.4bn
Q2 202311 holders, $1.6bn27 holders, $24.7bn
Q3 202312 holders, $1.4bn33 holders, $24.3bn
Q4 202311 holders, $1.1bn32 holders, $28.6bn
Q1 20249 holders, $1.7bn31 holders, $29.8bn
Q2 20248 holders, $1.9bn29 holders, $33.4bn
Q3 202410 holders, $2.5bn27 holders, $33.5bn
Q4 202410 holders, $2.4bn26 holders, $28.5bn
Q1 202518 holders, $3.3bn21 holders, $35.4bn
Q2 202511 holders, $2.9bn21 holders, $32.3bn
Q3 202512 holders, $2.2bn22 holders, $25.9bn
Q4 202512 holders, $1.7bn26 holders, $31.8bn
Q1 20269 holders, $1.3bn25 holders, $31.8bn
Q2 20268 holders, $1.0bn26 holders, $34.6bn
ALC

Alcon AG

Holders
9
Reported value
$1.7bn
Buyers
7
Sellers
3

Breadth +4 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
31
Reported value
$29.8bn
Buyers
16
Sellers
19

Breadth -3 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ALC (1)

Arrowstreet Capital LP

Only VRTX (23)

Acadian Asset Management LLC, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., ExodusPoint Capital Management LP, Invesco Ltd, Man Group PLC, MFS Investment Management, Millennium Management LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, Voloridge Investment Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →